Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study.
postembolization syndrome
prophylactic steroids
renal angiomyolipoma
Journal
Interventional radiology (Higashimatsuyama-shi (Japan)
ISSN: 2432-0935
Titre abrégé: Interv Radiol (Higashimatsuyama)
Pays: Japan
ID NLM: 101745449
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
received:
01
04
2021
accepted:
19
07
2022
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Postembolization syndrome (PES) after renal arterial embolization (RAE) can reduce the patient's tolerance of the procedure and extend the length of hospital stay. We aimed to assess the efficacy of steroid administration in preventing PES in patients undergoing RAE for angiomyolipoma (AML). Between May 2004 and March 2020, 29 RAE procedures in 26 patients with AML were performed. Patient information, including age, sex, tumor size, tuberous sclerosis complex-associated/sporadic AML, hemorrhagic/nonhemorrhagic AML, embolic material, steroid use, medication type, some blood laboratory parameters, hospital stay, and PES occurrence were retrospectively obtained. The prophylactic steroid protocol used in the study was as follows: 250 mg of intravenous methylprednisolone (Solu-Medrol) 2 h before the RAE procedure, followed by 2 days of intravenous prednisolone (Predonine; 2 mg/kg/day), which was tapered by halving the dose every 2 days within the course of 2 weeks. After the discharge, intravenous prednisolone was changed to oral prednisolone (Predonine). PES was defined as the presence of fever, pain, nausea, or vomiting. Data were compared between the steroid and non-steroid groups and between PES and non-PES groups. The PES incidence rate was 76%, and a comparison between the steroid and non-steroid groups revealed that steroid use significantly decreased the incidence of PES (P < 0.001), including fever (P < 0.001), pain (P = 0.005), and nausea (P = 0.028). The use of anti-inflammatory drugs during the hospital stay was significantly lower in the steroid group (P = 0.019). Moreover, in the steroid group, C-reactive protein level was significantly lower (P = 0.006), whereas white blood cell count was significantly higher (P = 0.004). Conversely, the median length of hospital stay was not significantly shorter in the steroid group (P = 0.292). The prophylactic use of steroids before and after embolization of renal AML may be effective in preventing PES in this small retrospective study.
Identifiants
pubmed: 36936258
doi: 10.22575/interventionalradiology.2021-0015
pmc: PMC10017270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-6Informations de copyright
© 2023 Japanese Society of Interventional Radiology.
Déclaration de conflit d'intérêts
None
Références
J Vasc Interv Radiol. 2010 Oct;21(10):1479-86
pubmed: 20870162
BMC Gastroenterol. 2015 Aug 04;15:96
pubmed: 26239844
J Vasc Interv Radiol. 2013 Mar;24(3):326-31
pubmed: 23380736
J Urol. 2016 Apr;195(4 Pt 1):834-46
pubmed: 26612197
J Urol. 2015 Sep;194(3):635-9
pubmed: 25916674
J Vasc Interv Radiol. 2001 Mar;12(3):321-6
pubmed: 11287509
Quant Imaging Med Surg. 2017 Feb;7(1):8-23
pubmed: 28275556
J Vasc Interv Radiol. 1994 Jul-Aug;5(4):587-91
pubmed: 7949715
J Vasc Interv Radiol. 2017 Jun;28(6):832-839
pubmed: 28291715
J Vasc Interv Radiol. 2000 Sep;11(8):1047-52
pubmed: 10997469
Hepatology. 2018 Feb;67(2):575-585
pubmed: 28746788
Eur Urol. 2009 May;55(5):1155-61
pubmed: 18440125
Acta Med Okayama. 2019 Aug;73(4):333-339
pubmed: 31439956
Cardiovasc Intervent Radiol. 2009 Nov;32(6):1171-8
pubmed: 19572171
Curr Med Imaging Rev. 2019;15(4):380-385
pubmed: 31989907
Am J Kidney Dis. 2002 May;39(5):966-71
pubmed: 11979340
Acta Med Port. 2018 Jan 31;31(1):22-29
pubmed: 29573765
Diagn Interv Imaging. 2015 Jun;96(6):579-87
pubmed: 25823980
J Vasc Interv Radiol. 2011 Oct;22(10):1388-95
pubmed: 21757371
Cardiovasc Intervent Radiol. 2016 Dec;39(12):1759-1764
pubmed: 27468838
J Vasc Interv Radiol. 2016 Oct;27(10):1542-9
pubmed: 27522275
BJU Int. 2007 Apr;99(4):881-6
pubmed: 17166242
J Vasc Interv Radiol. 1998 Mar-Apr;9(2):255-61
pubmed: 9540909
Am J Kidney Dis. 2006 Jan;47(1):95-102
pubmed: 16377390
J Vasc Interv Radiol. 2018 Jul;29(7):958-965
pubmed: 29398412
BJU Int. 2010 Feb;105(3):390-4
pubmed: 19709070
Cancer Nurs. 2016 Sep-Oct;39(5):E1-E18
pubmed: 26484962